Cargando…

Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases

SIMPLE SUMMARY: General toxicity for the organism is a major drawback of anticancer drugs. Development of new generation chemotherapeutics requires the knowledge about macromolecules critical for tumor cell viability. Among these species (called therapeutic targets), the protein kinases are the esta...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusina, Polina, Gandalipov, Erik, Abdusheva, Yana, Panova, Maria, Burdenkova, Alexandra, Chaliy, Vasiliy, Brachs, Maria, Stroganov, Oleg, Guzeeva, Ksenia, Svitanko, Igor, Shtil, Alexander, Novikov, Fedor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417023/
https://www.ncbi.nlm.nih.gov/pubmed/37568583
http://dx.doi.org/10.3390/cancers15153766
_version_ 1785087921056907264
author Rusina, Polina
Gandalipov, Erik
Abdusheva, Yana
Panova, Maria
Burdenkova, Alexandra
Chaliy, Vasiliy
Brachs, Maria
Stroganov, Oleg
Guzeeva, Ksenia
Svitanko, Igor
Shtil, Alexander
Novikov, Fedor
author_facet Rusina, Polina
Gandalipov, Erik
Abdusheva, Yana
Panova, Maria
Burdenkova, Alexandra
Chaliy, Vasiliy
Brachs, Maria
Stroganov, Oleg
Guzeeva, Ksenia
Svitanko, Igor
Shtil, Alexander
Novikov, Fedor
author_sort Rusina, Polina
collection PubMed
description SIMPLE SUMMARY: General toxicity for the organism is a major drawback of anticancer drugs. Development of new generation chemotherapeutics requires the knowledge about macromolecules critical for tumor cell viability. Among these species (called therapeutic targets), the protein kinases are the established enzymes. However, the parts of protein kinases that are supposed to be targeted by drugs can be structurally similar. Therefore, it is difficult to design the compounds that selectively bind and inactivate individual kinases, especially if the proteins comprise the evolutionarily conserved families. In the present study, a set of advanced approaches of computational chemistry and biochemistry was used for the structure-based design of new compounds to inhibit cyclin-dependent protein kinases (CDK), the enzymes mechanistically implicated in tumor biology. We demonstrated the advantages of the non-equilibrium (NEQ) thermodynamics method for a time-efficacious, accurate, and informative prediction of CDK inhibitory properties of new compounds. Importantly, NEQ-based predictions correlated with experimental testing. ABSTRACT: The rational design of cyclin-dependent protein kinase (CDK) inhibitors presumes the development of approaches for accurate prediction of selectivity and the activity of small molecular weight anticancer drug candidates. Aiming at attenuation of general toxicity of low selectivity compounds, we herein explored the new chemotype of imidazole-4-N-acetamide substituted derivatives of the pan-CDK inhibitor PHA-793887. Newly synthesized compounds 1–4 containing an aliphatic methyl group or aromatic radicals at the periphery of the scaffold were analyzed for the prediction of relative free energies of binding to CDK1, -2, -5, and -9 using a protocol based on non-equilibrium (NEQ) thermodynamics. This methodology allows for the demonstration of a good correlation between the calculated parameters of interaction of 1–4 with individual targets and the values of inhibitory potencies in in vitro kinase assays. We provide evidence in support of NEQ thermodynamics as a time sparing, precise, and productive approach for generating chemical inhibitors of clinically relevant anticancer targets.
format Online
Article
Text
id pubmed-10417023
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104170232023-08-12 Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases Rusina, Polina Gandalipov, Erik Abdusheva, Yana Panova, Maria Burdenkova, Alexandra Chaliy, Vasiliy Brachs, Maria Stroganov, Oleg Guzeeva, Ksenia Svitanko, Igor Shtil, Alexander Novikov, Fedor Cancers (Basel) Article SIMPLE SUMMARY: General toxicity for the organism is a major drawback of anticancer drugs. Development of new generation chemotherapeutics requires the knowledge about macromolecules critical for tumor cell viability. Among these species (called therapeutic targets), the protein kinases are the established enzymes. However, the parts of protein kinases that are supposed to be targeted by drugs can be structurally similar. Therefore, it is difficult to design the compounds that selectively bind and inactivate individual kinases, especially if the proteins comprise the evolutionarily conserved families. In the present study, a set of advanced approaches of computational chemistry and biochemistry was used for the structure-based design of new compounds to inhibit cyclin-dependent protein kinases (CDK), the enzymes mechanistically implicated in tumor biology. We demonstrated the advantages of the non-equilibrium (NEQ) thermodynamics method for a time-efficacious, accurate, and informative prediction of CDK inhibitory properties of new compounds. Importantly, NEQ-based predictions correlated with experimental testing. ABSTRACT: The rational design of cyclin-dependent protein kinase (CDK) inhibitors presumes the development of approaches for accurate prediction of selectivity and the activity of small molecular weight anticancer drug candidates. Aiming at attenuation of general toxicity of low selectivity compounds, we herein explored the new chemotype of imidazole-4-N-acetamide substituted derivatives of the pan-CDK inhibitor PHA-793887. Newly synthesized compounds 1–4 containing an aliphatic methyl group or aromatic radicals at the periphery of the scaffold were analyzed for the prediction of relative free energies of binding to CDK1, -2, -5, and -9 using a protocol based on non-equilibrium (NEQ) thermodynamics. This methodology allows for the demonstration of a good correlation between the calculated parameters of interaction of 1–4 with individual targets and the values of inhibitory potencies in in vitro kinase assays. We provide evidence in support of NEQ thermodynamics as a time sparing, precise, and productive approach for generating chemical inhibitors of clinically relevant anticancer targets. MDPI 2023-07-25 /pmc/articles/PMC10417023/ /pubmed/37568583 http://dx.doi.org/10.3390/cancers15153766 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rusina, Polina
Gandalipov, Erik
Abdusheva, Yana
Panova, Maria
Burdenkova, Alexandra
Chaliy, Vasiliy
Brachs, Maria
Stroganov, Oleg
Guzeeva, Ksenia
Svitanko, Igor
Shtil, Alexander
Novikov, Fedor
Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases
title Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases
title_full Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases
title_fullStr Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases
title_full_unstemmed Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases
title_short Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases
title_sort imidazole-4-n-acetamide derivatives as a novel scaffold for selective targeting of cyclin dependent kinases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417023/
https://www.ncbi.nlm.nih.gov/pubmed/37568583
http://dx.doi.org/10.3390/cancers15153766
work_keys_str_mv AT rusinapolina imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT gandalipoverik imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT abdushevayana imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT panovamaria imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT burdenkovaalexandra imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT chaliyvasiliy imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT brachsmaria imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT stroganovoleg imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT guzeevaksenia imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT svitankoigor imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT shtilalexander imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases
AT novikovfedor imidazole4nacetamidederivativesasanovelscaffoldforselectivetargetingofcyclindependentkinases